2295-P: Erectile Dysfunction in Type 2 Diabetes: Prevalence and Risk Factors in a Real-World Clinical Cohort

Introduction and Objective: Erectile dysfunction (ED) is common in type 2 diabetes (T2D), but studies often exclude comorbid patients, limiting generalizability. This study examines ED prevalence and risk factors in men with T2D in real-world clinical practice. Methods: This cross-sectional study enrolled 473 men with T2D aged ≥25 years at the Freedom from Diabetes Clinic, India. ED was assessed using the IIEF-5 questionnaire; depression and anxiety were evaluated with PHQ-9 and GAD-7 scales. Clinical variables included comorbidities (hypertension, dyslipidemia, chronic kidney disease [CKD], neuropathy), diabetes duration, treatment regimen, and HbA1c levels. Variables significant on univariate analysis (p<0.05) were entered into binary logistic regression. Results: Median (IQR) age was 47 years (13), diabetes duration 6.6 years (8). Poor glycemic control (HbA1c >7%) was seen in 67.7% of patients despite treatment: oral hypoglycemic agents (OHA) alone (77%), insulin plus OHA (5.5%), or no medications (17.3%). Overall, ED prevalence was 64%: no ED (35.9%), mild ED (31.9%), mild-to-moderate ED (19.9%), moderate ED (9.1%), severe ED (3.2%). Comorbidity prevalence was: hypertension (43%), dyslipidemia (46%), CKD (38%), hypothyroidism (8%), neuropathy (8%). Depression (score>5) and anxiety (score>5) prevalence was 46.5% and 40.6%, respectively. Multivariate analysis found following independent ED predictors: older age (OR 1.6, 95% CI 1.03-2.5), depression (OR 2.3, 95% CI 1.5-3.7), and insulin plus OHA therapy (n=26; 92% with ED, OR 5.6, 95% CI 1.2-26.9). Conclusion: ED affects two-thirds of men with T2D. Age, depression, and insulin-OHA therapy independently predict ED, highlighting metabolic and psychological contributions. Findings support routine ED screening and mental health assessment in diabetes care.